Datopotamab Deruxtecan + Rilvegostomig + Pembrolizumab
Phase 3Recruiting 1 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer
Trial Timeline
Apr 11, 2024 → Dec 28, 2029
NCT ID
NCT06357533About Datopotamab Deruxtecan + Rilvegostomig + Pembrolizumab
Datopotamab Deruxtecan + Rilvegostomig + Pembrolizumab is a phase 3 stage product being developed by Daiichi Sankyo for Non-Small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06357533. Target conditions include Non-Small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Non-Small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06357533 | Phase 3 | Recruiting |
Competing Products
20 competing products in Non-Small Cell Lung Cancer